Kornimate/medical-research-clean huggingface dataset:
atrial strain in septic shock

Conditions: Septic Shock; Left Atrial Strain; Right Atrial Strain; Transthoracic Echocardiography; Speckle Tracking; Echocardiographic Software; Reproducibility; Critical Care

Summary: septic shock is a critical condition associated with high mortality. transthoracic echocardiography is widely used to evaluate cardiac function and guide treatment. left and right atrial strain (las and ras) measured via speckle tracking echocardiography have shown prognostic value in cardiovascular diseases. however, differences exist between echocardiographic software, leading to challenges in result comparability. this study aims to compare las and ras measurements between echopac and uws software, evaluate autostrain technology, and assess reproducibility across observers. the study is non-interventional and will use retrospective echocardiographic data from patients treated for septic shock. the findings will contribute to improving measurement standardization in critically ill patients.


Eligibility criteria:
inclusion criteria: * age: \>18 years * adult patients admitted to critical care for septic shock (sepsis-3 definition) * tte performed as part of medical management * no objection to data usage exclusion criteria: * pregnancy * moderate to severe valvular regurgitation/stenosis (\>grade 2) * ventricular or supraventricular tachyarrhythmia (hr \>140 bpm) at the time of tte * poor echogenicity preventing las measurement * mechanical circulatory support * pacemaker dependence * patients under guardianship

Keywords: transthoracic echocardiography septic shock left atrial strain right atrial strain speckle tracking echocardiographic software autostrain bland-altman analysis reproducibility critical care
clinical efficacy of biomin f, colgate sensitive pro-relief and sensodyne rapid action dentifrices in dh

Conditions: Dentin Hypersensitivity

Summary: this will be multi-centered, triple blinded, randomized, four parallel treatments assigned study to compare clinical efficacy of commercially available dentifrices with placebo for immediate and sustained relief from dentin hypersensitivity after short term use. condition or disease: dentin hypersensitivity intervention/treatment: product 1; fluoro-calcium-phospho-silicate based biomin f product 2; pro-argin formula based colgate sensitive pro-relief product 3; strontium acetate based sensodyne rapid action product 4; sodium fluoride based colgate total

it is a randomized controlled clinical trial with non invasive topical intervention in 140 adult patients of 18 to 60 years age, that will be selected randomly after screening and diagnosis of dentin hypersensitivity, in dental out patient department of periodontology. written informed consent will be obtained. participants will be allocated randomly into four equal study arms for parallel treatment assignment with dentifrices named biomin f, colgate sensitive pro-relief trade mark,sensodyne rapid action trade mark and colgate total trade mark dentifrices. colgate total trade mark dentifrices does not claim pain relief in dentin hypersensitivity. interim efficacy will be assessed immediately after topical application on sensitive teeth, in one minute, after 5 minutes, on day three and week 4 respectively. dentin hypersensitivity will be tested with mechanical stimulus, evaporative air blast stimulus and water jet stimulus. it will be measured on visual analogue scale and schiff cold air sensitivity scale (scass). statistical analysis will be done using anova in statistical package for social sciences software 21.

Eligibility criteria:
inclusion criteria: * subjects with at least two teeth sensitive to cold, touch and air blow stimulus * sensitive teeth anterior to molars either due to erosions or abrasions with or without associated gingival recession * teeth with linear visual analogue scale (vas) score of ≥ 4 and code 2 of schiff cold air sensitivity scale on screening. exclusion criteria: * subjects with worst pain response at 100mm on vas.(visual analog scale) * teeth with orthodontic or prosthetic appliances, caries, restorations or cracks * localized or generalized gingivitis or pulpitis with heavy calculus * periodontal surgery in the preceding three months * patients using any desensitizing tooth paste or mouth wash up to six weeks before study and taking drugs like anti-inflammatory, sedatives, tranquilizers, analgesics in routine. * pregnant or breastfeeding females.

Keywords: dentine hypersensitivity dentine sensitivity oral dentifrices bio-active glasses
brief intervention to reduce fear of public speaking

Conditions: Social Anxiety Disorder

Summary: the study will test the efficacy of propranolol or placebo, administered after retrieval of a previously acquired public speaking fear, in reducing fear and avoidance of public speaking.

twenty subjects with performance-only type of social anxiety disorder will be enrolled in the study. participants will complete baseline assessments of fear and avoidance of public speaking. participants will be randomly assigned to a single dose of propranolol 40mg or placebo, administered immediately after a fear activation procedure. primary outcome assessment will be self-reported fear of public speaking and avoidance behavior in a behavioral avoidance task 2 weeks after the intervention.

Eligibility criteria:
inclusion criteria: * 18-60 years of age at the time of consent * principal diagnosis of social anxiety disorder, performance only type * has clinically significant fear of public speaking * physically healthy * if female, non-pregnant and not nursing * off all psychotropic drug for at least 4 weeks * a level of understanding sufficient to provide written informed consent to all required study tests and procedures. exclusion criteria: * history of other serious psychiatric disorder * current major depressive disorder * presence of developmental disorder or intellectual disability * sad patients with sad not of the performance only type * women who are pregnant or nursing * current use of psychiatric medication * current substance use disorder * persons planning to start another treatment during the study period. * any significant medical condition that might increase the risk or participation (e.g., seizure disorder, respiratory disorders \[e.g., bronchial asthma\], cardiovascular disease \[e.g., congestive heart failure, heart arrhythmias, sinus bradycardia and greater than first degree block \], low blood pressure \[ \< 90/60\], diabetes, liver or kidney disorders) * use of medications that might negatively interact with propranolol (e.g., ace inhibitors; catecholamine depleting drugs, such as reserpine; calcium channel blockers; digitalis glycosides; haloperidol; chlorpromazine; aluminum hydroxide gel; phenytoin; phenobarbitone; rifampin; antipyrine; lidocaine; cimetidine; theophylline)

Keywords: propranolol public speaking anxiety
faza petmri gastro-oesophageal study

Conditions: Metastasized Gastro-Oesophageal Cancer

Summary: this is a single arm, pilot study of pet/mri scan with radiotracer 18f-fluoroazomycin arabinoside (faza) before and after standard of care platinum-based chemotherapy for patients with metastasized gastro-oesophageal cancer. gastroesophageal cancer (gec) accounted for 2,3000 deaths in canada in 2017 and majority of the patients present or develop metastatic disease following diagnosis. these patients are treated with platinum-based chemotherapy. there is currently no biomarker that can be used to predict the therapy responses. additionally, patients that do not respond to the chemotherapy often deteriorate rapidly and are unable to receive second line therapy. intratumoral hypoxia (low oxygen concentration) is a signature feature of aggressive and resistant tumour phenotype. accurately predicting hypoxia in solid tumours offers an innovative and rational pradigm for predicting therapy responses. pet/mri is an imaging technique combining the positron emission tomography (pet) scan with magnetic resonance imaging (mri) scan. a radiotracer called 18f-fluoroazomycin arabinoside (faza) is used as a type of "dye" in the pet/mri scan. the primary goal of the study is to validate faza pet/mri as a biomarker of hyupoxia in setting of gastro-oesophageal carcinoma. patients with gec will undergo faza pet/mri scan before and after the standard of care chemotherapy. this would be correlated with clinical outcome in patients with metastatic gec that have different responses to chemotherapy. ultimately, we hope that the use faza pet/mri in the study can help select the most effective treatment method for advanced gec to extend life and improve quality of life while minimizing toxicity and healthcare costs. the study subjects' clinical management will not be changed based on the pet-mr scan within the trial.


Eligibility criteria:
inclusion criteria: * age ≥18 years * patients with de novo or secondary metastasized gastro-oesophagesal cancer (adenocarcinoma) * glomerular filtration rate\> 45 ml/min * no allergy to contrast agents exclusion criteria: * contraindication for mr as per current institutional guidelines * inability to lie supine for at least 30 minutes * any patient who is pregnant or breastfeeding * any patient unable or unwilling to provide informed consent * patients who are allergic to ethanol as the faza preparation contains ethanol
study comparing the effect of ligamentum teres cardiopexy on de novo gerd post lsg

Conditions: GERD

Summary: the aim of this study is to investigate the effect of ligamentum teres cardiopexy on incidence of de novo gerd.

laparoscopic sleeve gastrectomy (lsg) is now the most commonly performed bariatric surgery world wide. the results of lsg on outcomes of gerd are conflicting. it has been reported to increase the severity of pre existing gerd and also to cause new onset gerd in considerable number of patients. in this study the effect of adding a novel procedure i.e. ligamentum teres cardiopexy,(ltc) to regular lsg on occurence of de novo gerd will be investigated. de novo gerd has been found to occur in 20% of cases post lsg. this study is a randomized, prospective, parallel group, controlled trial to compare the effect of lsg versus lsg with ltc on occurence of de novo gerd. this is a single center based trial, being conducted in gem hospital and research center, coimbatore, tamil nadu, india. the trial has been approved by gem research ethics committee. investigators are planning to enroll patients who are not having any objective or subjective evidence of gerd. the participants will be optimized as per institutional bariatric surgery protocol. after complete evaluation and optimization, participants will be randomized by computer generated random numbers into either lsg or lsg with ltc group. the demographic data, preoperative gerd - q scores, 24 hour ph study, intra operative details will be recorded. post operative details during each follow up will be recorded, which will include excess weight loss, gerd - q scores. at 6 months follow up repeat 24 hour ph study will be done to assess the status of gerd objectively. the trial duration is expected to be of 1 year where in investigators will be recruiting patients for 6 months.

Eligibility criteria:
inclusion criteria: * candidate for bariatric surgery according to ifso - apc guidelines * no evidence (objective and subjective) of gerd exclusion criteria: * presence of gerd either by history or by 24 hr ph study

Keywords: de novo gerd
comparison of methods in post operative knee arthroscopy rehabilitation

Conditions: ACL Tear

Summary: the aim of this study is to investigate the efficacy of blood flow restriction (bfr) therapy in post-operative rehabilitation following knee arthroscopy for primary acl reconstruction. bfr has been shown to effect time to return to activity and strength postoperatively. this study aims to analyze the effects of bfr therapy in patients who underwent primary acl reconstruction surgery compared to controls. participants will be randomized into either a treatment (bfr cuff) or control (no bfr cuff) group. all participants will follow standard of care (soc) physical therapy protocol for 12 weeks after surgery according to their treatment group. strength and patient outcome measures will be recorded throughout the 2 year study period.

the aim of this study is to investigate the efficacy of blood flow restriction (bfr) therapy in post operative rehabilitation following knee arthroscopy. the current standard of care and post-operative pain levels can limit patients from applying load necessary to increase muscle size and strength development due to partial weight baring after surgery. we hypothesize that immediate and consistent use of bfr augmenting our current standard post operative knee arthroscopy rehabilitation protocol will result in greater improvement in strength and quicker achievement of phase-based rehabilitation goals. we hypothesize that these objective improvements in strength will correlate with clinically meaningful improvement in tegner activity scale, international knee documentation committee (ikdc), return to sport, lower extremity functional scale (lefs), pain and resiliency (patient reported outcome, pro) scores indicative of greater functional recovery compared to our standard rehabilitation protocol alone.

Eligibility criteria:
inclusion criteria: * patients undergoing primary knee arthroscopy for acl reconstruction without meniscus repair * completing initial 12 weeks of physical therapy at the steadman hawkins clinic in denver * patients with access to smartphone device exclusion criteria: * bilateral knee surgeries to be performed within 12 weeks of each other * patients received meniscus repairs, chondral lesion repair/transplants, * prior surgery on the same knee * anyone who meets the following contraindications for bfr therapy: * deep vein thrombosis (dvt) * pulmonary embolism * hemorrhagic/thrombolytic stroke * clotting disorders * hemophilia or taking blood thinners * pregnant or up to 6 months post-partum * untreated hypertension * untreated hypotension * rhabdomyolysis or recent traumatic injury 2. exclusion criteria will be evaluated via the medical record as well as by the expert opinion of the physician. 3. if at any point in the study a subject develops one of the above contraindications, they will be removed from the study. 4. if a subject becomes pregnant while participating in the intervention portion of the study, they will be removed.
enriching clinical trials requiring amyloid positivity with practice effects

Conditions: Alzheimer Disease; Mild Cognitive Impairment

Summary: the primary objective of this study is to demonstrate that individuals with low short-term practice effects (stpe) on cognitive testing are more likely to be identified as "positive" on amyloid imaging than individuals with high stpe. stpe may also inform us about other ad-related biomarkers, including hippocampal volumes, functional connectivity, and apoe status. by realizing the aims of this pragmatic study, we hope to be able to offer more economical and efficient screening of potential participants for clinical trials, which would reduce participant burden and financial costs.


Eligibility criteria:
inclusion criteria: * 65 years or older * identified as intact, mild cognitive impairment, or alzheimer's disease * able to complete study procedures * all participants must have a collateral source (e.g. spouse, adult child, caregiver, close friend) available to briefly comment on the cognitive abilities and daily functioning of the participant. if the participant is diagnosed with probable ad dementia, a legally authorized representative (e.g. spouse, adult child) must be available to provide informed consent for the participant. exclusion criteria: * history of major stroke, head injury with loss of consciousness of \>30 minutes, or other neurological/systemic illness that may affect cognition * current or past major psychiatric illness (e.g., schizophrenia, bipolar affective disorder) * history of substance abuse * current use of antipsychotics or anticonvulsant medications * known allergic or hypersensitivity reactions to previously administered radiopharmaceuticals. * need for monitored sedation or anesthesia during pet or mri scanning. * claustrophobia to a degree that the individual cannot undergo pet or mri imaging * history of metal injury which precludes the individual from undergoing mri imaging * evidence of stroke or mass lesion on a ct or mri scan * history of radiation therapy to the brain * history of significant major medical illnesses, such as cancer or aids. * inadequate vision, hearing, and manual dexterity to participate in the cognitive assessments. * 15-item geriatric depression scale score of \>5 * clinical dementia rating score of \>1 * mini mental state examination score of \<20

Keywords: practice effects amyloid imaging
reliability and validity of a new device measuring spinal rotation on the transverse plane

Conditions: Scoliosis

Summary: the purpose of this research is to investigate the reliability and validity of a new device similar to a scoliometer. the intended name of the device will be scolioscope

οne cohort of participants will be used and the reliability of the equipment will be used to test/retest the repeatability of the measurements the validity will be measured against a gold standard for measuring angles

Eligibility criteria:
inclusion criteria: lumbar and thoracic scoliosis - exclusion criteria: recent spinal surgery, cancer, spinal fixation -
treatment for acute postoperative voiding dysfunction

Conditions: Urinary Retention

Summary: if patients are unable to have their foley catheter removed because their bladder is not emptying well, they may be eligible for study participation. this study is designed to evaluate whether posterior tibial nerve stimulation is effective in improving bladdder function after surgery. study participation is limited to one day.

if patients fail a voiding trial (the test done to see if a foley catheter is ready to be removed after surgery), they may be offered participation in this trial. patients are randomized to receive active treatment or a sham treatment. a small, accupuncture-type needle is inserted through the skin just above the ankle. a small, battery-powered generator will be attached to the needle. the generator will give a low-voltabe stimulation which is adjusted for comfort level and applied for 30 minutes. after treatemnt, the voiding trial will be repeated.

Eligibility criteria:
inclusion criteria: * first voiding trial after urogynecological surgery shows that bladder is not emptying well. exclusion criteria: * patient declines participation.

Keywords: voiding dysfunction
sedation and ease of weaning from mechanical ventilation

Conditions: Respiratory Failure; Midazolam Overdose; Chronic Obstructive Pulmonary Disease; Weaning Failure

Summary: daily interruption of sedation is one of the modalities which is known to enhance early weaning and separation from mechanical ventilation . daily sedation interruption is also known to help decreasing incidence of ventilator associated pneumonia. the new modality is no sedation.

there is an increase of incidence of chronic obstructive lung disease associated respiratory failure which necessitates invasive mechanical ventilation. it is well known that one of the bundles for enhanced recovery of such cases is the daily interruption of sedation . recently studies have demonstrated the feasibility of just using sedation for initiation of mechanical ventilation, then utilization of no sedation technique as a more this offers less side effects .

Eligibility criteria:
inclusion criteria: * obstructive lung disease * respiratory failure * invasive mechanical ventilation exclusion criteria: * neurological deficit * cognitive dysfunction * extensive malignancy * septic shock
pecs block vs. multimodal analgesia for prevention of persistent postoperative pain in breast surgery

Conditions: Breast Cancer; Breast Cancer Female; Cancer of Breast

Summary: in this double blinded randomized placebo-controlled trial, 160 subjects scheduled for breast surgery involving the axilla will be administered a multimodal pain regimen including acetaminophen, dexamethasone, celecoxib, and gabapentin. 80 subjects will also receive a pectoral nerve blocks i and ii (pecs i and ii block) preoperatively.


Eligibility criteria:
inclusion criteria: * scheduled to undergo elective breast cancer surgeries at barnes-jewish hospital: * unilateral axillary dissection * unilateral modified radical mastectomy * mastectomy with same day unilateral reconstruction * unilateral sentinel lymph node biopsy (slnb) * partial mastectomy with unilateral slnb * simple mastectomy with unilateral slnb * at least 18 years of age. * able to understand and willing to sign an institutional review board (irb)-approved written informed consent document. * enrollment in the satisfy-sos study (wustl irb# 201203088, nct02032030). exclusion criteria: * planned for bilateral axillary or bilateral reconstruction surgery. * previous surgery on the surgical breast and/or axilla with the exception of partial mastectomy or sentinel lymph node biopsy * pre-existing pain in the axilla affecting the ability to use extremity for activities of daily living or requiring medication for treatment. * current or past medical history of liver disease or cirrhosis with an elevated inr \>1.4 or currently elevated transaminase levels. * known contraindications to peripheral nerve block placement. * pregnant or breastfeeding. * history of allergic reactions attributed to compounds of similar chemical or biologic composition * planned additional surgery to the surgical breast or axilla in the next year (exception would be minor surgery to breast but not axilla such as simple tissue expander replacement or lumpectomy)